Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?

Reported by Yahoo Finance · Published 15 Aug 2026, 6:23 AM MYT (1 d ago)

Summary

Source & full coverage: this summary is aggregated from Yahoo Finance, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at Yahoo Finance →

Most Recent

Disney, Square Enix preview 'Kingdom Hearts 4' video game at fan convention 3 hr ago SpaceX Stock Is Down 33% From Its High. Elon Musk Expects Revenue to Rise 53-Fold to $1 Trillion by 2030. 6 hr ago I survived two years as prime minister in a hit new game - then my cabinet deserted me 6 hr ago Which Is the Better Energy ETF: State Street's Fossil Fuel XOP or iShares' Clean Energy ICLN? 6 hr ago US to tell partners they must pick sides in AI race with China 6 hr ago Vanguard's VGLT or Schwab's SCHQ: Which Long-Term Treasury ETF Is the Better Buy? 7 hr ago

EconPulse

Markets. Economy. Malaysia & The World.

Independent economic news aggregation for Malaysia, Asia and global markets, updated throughout the day.

Company

About Us Editorial Standards & Corrections Privacy Policy

Work With Us

Submit a Press Release Partnerships & Advertising Contact Us RSS Feed

Contact

editor@econpulse.my

Editorial & newsroom enquiries answered within 1–2 business days.

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?

Summary

More in Markets

SpaceX Stock Is Down 33% From Its High. Elon Musk Expects Revenue to Rise 53-Fold to $1 Trillion by 2030.

Which Is the Better Energy ETF: State Street's Fossil Fuel XOP or iShares' Clean Energy ICLN?

Vanguard's VGLT or Schwab's SCHQ: Which Long-Term Treasury ETF Is the Better Buy?

Block’s (XYZ) EPS Surged 65%, So Why Did the Stock Drop?

Pandora opens unexpected box as silver price drops

Snowflake vs. Verizon: Which Technology Stock Is a Better Buy in 2026?